A molecular docking study of estrogenically active compounds with 1,2-diarylethane and 1,2-diarylethene pharmacophores.

Numerous selective estrogen receptor modulators (SERMs) have been synthesized and assayed in recent years. The focus of this study is to apply coarse-grain molecular docking procedures coupled with fine-grain all-atom force field optimization strategies to shed light on the binding mechanisms of currently available estrogen receptor-active compounds. Although the mechanics of ligand binding in estrogen receptors is generally well understood, there is room for surprises. In this paper computational evidence corroborating the experimentally observed type I agonistic binding mode for estradiol (E2) and diethylstilbesterol (DES) and the type II antagonistic binding mode for 4-hydroxytamoxifen and raloxifen is presented. Included in this type I agonistic mode are the DES derivatives, transstilbene and 1,2-diaryldiaminoethane. In addition, a novel 'type II agonistic' binding mode for 2,3-diarylimidazolines, 4,5-diarylimidazoles, 2,3-diarylpiperazines is introduced. This mode is stabilized by suggesting alternative hydrogen bond anchor points in the ligand binding domain as potential leads for future drug design.

[1]  William A. Goddard,et al.  Fidelity of Phenylalanyl-tRNA Synthetase in Binding the Natural Amino Acids , 2003 .

[2]  J. Gustafsson,et al.  Estrogen receptor beta--a new dimension in estrogen mechanism of action. , 1999, The Journal of endocrinology.

[3]  M. Singh,et al.  Structure-based drug design: synthesis, crystal structure, biological evaluation and docking studies of mono- and bis-benzo[b]oxepines as non-steroidal estrogens. , 2003, Bioorganic & medicinal chemistry.

[4]  Wolfgang Sippl,et al.  Binding affinity prediction of novel estrogen receptor ligands using receptor-based 3-D QSAR methods. , 2002, Bioorganic & medicinal chemistry.

[5]  B. Rabenstein,et al.  Electron transfer between the quinones in the photosynthetic reaction center and its coupling to conformational changes. , 2000, Biochemistry.

[6]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[7]  G M Shepherd,et al.  Molecular mechanisms underlying differential odor responses of a mouse olfactory receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Gust,et al.  (4R,5S)/(4S,5R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines: ligands for the estrogen receptor with a novel binding mode. , 2002, Journal of medicinal chemistry.

[9]  Carolyn L. Smith,et al.  Molecular mechanisms of selective estrogen receptor modulator (SERM) action. , 2000, The Journal of pharmacology and experimental therapeutics.

[10]  V. Jordan,et al.  Molecular classification of estrogens. , 2001, Cancer research.

[11]  M Carlquist,et al.  Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.

[12]  R. Gust,et al.  Synthesis, structural evaluation, and estrogen receptor interaction of 2,3-diarylpiperazines. , 2002, Journal of medicinal chemistry.

[13]  W. A. Toscano,et al.  QSAR Models of the in vitro Estrogen Activity of Bisphenol A Analogs , 2003 .

[14]  J. Gustafsson,et al.  Role of estrogen receptor beta in estrogen action. , 2001, Annual review of physiology.

[15]  D. Bentrem,et al.  Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. , 2003, Cancer research.

[16]  F. Cramer,et al.  Phenylalanyl-tRNA synthetase from yeast and its discrimination of 19 amino acids in aminoacylation of tRNA(Phe)-C-C-A and tRNA(Phe)-C-C-A(3'NH2). , 1996, European journal of biochemistry.

[17]  S. Gapstur,et al.  Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. , 2001, Journal of the National Cancer Institute.

[18]  Todd J. A. Ewing,et al.  Critical evaluation of search algorithms for automated molecular docking and database screening , 1997 .

[19]  Peter L. Freddolino,et al.  Prediction of structure and function of G protein-coupled receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T Lengauer,et al.  Two-stage method for protein-ligand docking. , 1999, Journal of medicinal chemistry.

[21]  M. L. Connolly.  Analytical molecular surface calculation , 1983 .

[22]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[23]  Johann Gasteiger,et al.  A new model for calculating atomic charges in molecules , 1978 .

[24]  Peter Wolohan,et al.  CoMFA and docking study of novel estrogen receptor subtype selective ligands , 2003, J. Comput. Aided Mol. Des..

[25]  V. Jordan,et al.  Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. , 2003, Journal of medicinal chemistry.

[26]  M. Mor,et al.  Synthesis, pharmacological evaluation, and structure-activity relationships of benzopyran derivatives with potent SERM activity. , 2004, Bioorganic & medicinal chemistry.

[27]  Todd J. A. Ewing,et al.  DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..

[28]  Robert Powers,et al.  Identification of novel estrogen receptor α antagonists , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[29]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[30]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[31]  Hong Liu,et al.  Estrogen receptor α mediated induction of the transforming growth factor α gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[33]  R. Gust,et al.  Investigations of new lead structures for the design of selective estrogen receptor modulators. , 2001, Journal of medicinal chemistry.

[34]  D. Thompson,et al.  Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. , 1998, Journal of medicinal chemistry.